Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9
Phase 2
Completed
- Conditions
- Cocaine-Related DisordersSubstance-Related Disorders
- Registration Number
- NCT00000274
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Side effects Psychiatric symptoms Drug use Cocaine craving
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie flupenthixol and haloperidol's efficacy in treating cocaine dependence in schizophrenia patients?
How do flupenthixol and haloperidol compare to standard antipsychotics in managing cocaine abuse among individuals with schizophrenia?
Are there specific biomarkers that predict response to flupenthixol or haloperidol in cocaine-dependent schizophrenia patients?
What are the known adverse events associated with flupenthixol and haloperidol in the treatment of cocaine abuse in schizophrenia, and how are they managed?
What other dopamine receptor antagonists or combination therapies have shown promise in treating cocaine abuse in schizophrenia patients?
Trial Locations
- Locations (1)
New York State Psychiatric Institute
🇺🇸New York, New York, United States
New York State Psychiatric Institute🇺🇸New York, New York, United States